EXHIBIT 10.1 ------------ LICENSE AND DEVELOPMENT AGREEMENT --------------------------------- This License and Development Agreement ("Agreement") is made and entered into effective as of March 24, 2006 (the "Effective Date") by and between Simtek...License and Development Agreement • March 30th, 2006 • Simtek Corp • Semiconductors & related devices • California
Portions of this exhibit marked [*] are requested to be treated confidentially. LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • May 11th, 2018 • Cerecor Inc. • Pharmaceutical preparations • New York
This LICENSE AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of February 16, 2018 (the “Effective Date”) by and between Cerecor, Inc., a Delaware corporation having an address at 400 East Pratt Street, Suite 606, Baltimore, MD 21202 (“Cerecor”), and Flamel Ireland Limited, operating under the trade name of Avadel Ireland, an Irish limited company having an address at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15 Ireland (“Avadel”). Avadel and Cerecor may be referred to herein individually as a “Party” or collectively, as the “Parties.”
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), is entered into as of the Effective Date by and between THE MEDICINES COMPANY, a Delaware corporation located at 8 Sylvan Way, Parsippany, N.J. 07054 (“MDCO”), and EAGLE PHARMACEUTICALS, INC., a Delaware corporation located at 470 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677 (“Eagle”).
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • November 8th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • California
THIS LICENSE AND DEVELOPMENT AGREEMENT is made and entered into as of June 30, 1998 (the “Effective Date”) by and between METABOLEX, INC., a Delaware corporation with a place of business at 3876 Bay Center Place, Hayward, CA 94545 (“Metabolex”), and DIATEX, INC., a Texas corporation with a place of business at 105 Elm Spring Lane, San Antonio, TX 78231 (“DiaTex”). Metabolex and DiaTex may be referred to herein as a “Party” or, collectively, as “Parties.”
AMENDMENT TO AMENDED AND RESTATED TECHNOLOGY LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • November 13th, 2023 • FreeCast, Inc. • Services-computer processing & data preparation • Florida
THIS AMENDMENT TO AMENDED AND RESTATED TECHNOLOGY LICENSE AND DEVELOPMENT AGREEMENT is entered into on July 1, 2013 by and between Nextelligence, Inc., a Delaware corporation (“Nextelligence”), and FreeCast, Inc., a Florida corporation (the “Company”).
ARTICLE 1 DEFINITIONSLicense and Development Agreement • November 15th, 2004 • Novadel Pharma Inc • Pharmaceutical preparations • New York
ADDENDUM TO DRUG LICENSE AND DEVELOPMENT AGREEMENT by and between LANTERN PHARMA, INC. and ONCOLOGY VENTURE, APSLicense and Development Agreement • April 16th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations
This Addendum is attached to and forms part of the DRUG LICENSE AND DEVELOPMENT AGREEMENT dated May 23, 2015 (hereinafter the “Addendum”), between Oncology Venture APS (Company Registration no. 34 62 35 62), a Danish corporation having its principal offices at Venlighedesvej 1, 2970 Hørsholm, Denmark (hereinafter “OV”), and Lantern Pharma, Inc, (Company Registration no. ______________________________ ) a Texas corporation having its principal place of business at 211 N Ervay Street, Suite 404, Dallas, TX 75201 U.S.A. (hereinafter “LP”) as of February 8, 2016 (the “EFFECTIVE DATE”) (hereinafter the “Addendum”). LP and OV are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. To the extent that any of the terms or conditions contained in this Addendum may contradict or conflict with any of the terms or conditions of the Drug License and Development Agreement dated May 23, 2015, it is expressly understood and agreed that the terms of this Addendum sh
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • February 16th, 2016 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations • New Jersey
This License and Development Agreement (“Agreement”) is made and entered into as of this June 5, 2015 (the “Effective Date”) by and between Bayer HealthCare LLC, with offices at 100 Bayer Blvd., Whippany, NJ 07981 (“Bayer”), and Acura Pharmaceuticals, Inc., with offices at 616 N. North Court, Palatine IL 60067 (“Acura”). Bayer and Acura each are referred to herein as a “Party” and collectively as the “Parties.”
Licensing and option agreement for iSONEP for wet age-related macular degenerationLicense and Development Agreement • February 2nd, 2022 • New York
Lpath has entered into an agreement providing Pfizer with an exclusive option for a worldwide license to develop and commercialize iSONEPTM for the treatment of wet age-related macular degeneration (wet AMD) and other ophthalmology disorders.
AMENDMENT NO. 2 TO DRUG LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • April 16th, 2020 • Lantern Pharma Inc. • Pharmaceutical preparations
This Amendment Number Two (“Amendment No. 2”), to the existing and in-force Drug License And Development Agreement (the “Agreement”) between the parties hereto (effective as of May 23, 2015), is entered into by and between Oncology Venture A/S, a Danish corporation having its principal offices at Venlighedesvej 1, 2970 Hørsholm, Denmark (“OV”), and Lantern Pharma, Inc., a Texas corporation having its principal place of business at 211 N Ervay Street, Suite 404, Dallas, TX 75201 U.S.A. (“LP”) as of February 11, 2016 (the “Effective Date”). LP and OV are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • March 25th, 2015 • Affimed N.V. • Pharmaceutical preparations • New York
ORDERED that judgment on priority as to Count 1 (the sole count in the interference: Paper 1, pages 6-7) is awarded against Junior Party Kontermann.
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed...License and Development Agreement • November 14th, 2007 • Novadel Pharma Inc • Pharmaceutical preparations • New Jersey
THIS AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), dated as of July 31, 2007 (the “Execution Date”), is entered into by and between NOVADEL PHARMA, INC., a Delaware corporation (“NovaDel”), and HANA BIOSCIENCES, INC., a Delaware corporation (the “Licensee”). NovaDel and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
ContractLicense and Development Agreement • December 19th, 2005 • NUCRYST Pharmaceuticals Corp. • Pharmaceutical preparations • Alberta
[***] indicates that text has been omitted which is the subject of a confidential treatment request. This text has been filed separately with the SEC.
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • August 11th, 2016 • Collegium Pharmaceutical, Inc • Pharmaceutical preparations • New York
This License and Development Agreement (“Agreement”) is made as of May 11, 2016 (the “Effective Date”) by and between BioDelivery Sciences International, Inc., a Delaware corporation with its principal offices at 4131 Parklake Avenue, Suite 225, Raleigh, North Carolina 27612 (“Parent”), its wholly-owned subsidiary Arius Pharmaceuticals, Inc., a Delaware corporation with an office at the same address (“Arius”, and together with Parent, “BDSI”), and Collegium Pharmaceutical, Inc., a Virginia corporation with its principal office at 780 Dedham Street, Suite 800, Canton, MA 02021 (“Collegium”). BDSI and Collegium are sometimes referred to collectively herein as the “Parties” or singly as a “Party.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. License and Development Agreement By and between Arrow International Limited 57 St. Christopher Street Valletta, VLT 08, Malta...License and Development Agreement • August 8th, 2008 • Sepracor Inc /De/ • Pharmaceutical preparations • New York
This License and Development Agreement (this "Agreement"), dated as of April 30, 2008 is being entered into by and between Arrow International Limited, a Malta corporation having its principal office at 57 St. Christopher Street, Valletta, VLT 08, Malta, and its Affiliates (collectively referred to as "Arrow"), and Sepracor Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 84 Waterford Drive, Marlborough, MA 01752, USA ("Sepracor"). Each or both of Arrow and Sepracor are hereinafter referred to as "Party" or "Parties", as intended in the given context.
EXHIBIT 10.13 SOFTWARE SALE, LICENSE AND DEVELOPMENT AGREEMENT This is a Software Sale, License and Development Agreement ("Agreement") dated as of January 20, 1999, (the "Effective Date") by and between Empower Health Corporation ("EHC"), a Texas...License and Development Agreement • June 4th, 1999 • Drkoop Com • Services-misc health & allied services, nec • Delaware
1 EXHIBIT 10.22 [Confidential treatment has been requested for portions of this exhibit. The confidential portions have been redacted and are denoted by [**]. The confidential portions have been separately filed with the commission.] LICENSE AND...License and Development Agreement • February 18th, 1997 • Ilex Oncology Inc • Services-medical laboratories
FIRST AMENDMENT TO AMENDED AND RESTATED SUPPLY, LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • May 15th, 2007 • VeriChip CORP • Communications equipment, nec
This First Amendment to the Amended and Restated Supply, License, and Development Agreement dated December 27, 2005, is dated May 9, 2007 (the “Amended Agreement”) by and between Digital Angel Corporation (“Digital Angel”) and VeriChip Corporation (“VeriChip”), both Delaware corporations.
SECOND AMENDMENT TOLicense and Development Agreement • October 18th, 2007 • Velcera, Inc. • Surgical & medical instruments & apparatus • New York
THIS SECOND AMENDMENT TO LICENSE AND DEVELOPMENT AGREEMENT (this "Agreement"), effective as of June 22, 2004 (the "Effective Date"), is entered into by and between NOVADEL PHARMA INC., a Delaware corporation ("NOVADEL"), and THE VETERINARY COMPANY, INC., a Delaware corporation (the "LICENSEE"). NovaDel and Licensee each may be referred to herein individually as a "Party," or collectively as the "Parties."
SECOND AMENDMENT TO LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • August 7th, 2019 • Athenex, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO LICENSE AND DEVELOPMENT AGREEMENT (this “Second Amendment”) is made and entered into as of this 18th day of June, 2019 (“Effective Date”) by and between Athenex, Inc., a corporation organized and existing under the laws of the state of Delaware, USA, with a principal place of business at 1001 Main Street, Suite 600, Buffalo, New York 14203 (“Athenex”), Almirall S.A., a corporation organized and existing under the laws of Spain with a principal place of business at Ronda del General Mitre 151, Barcelona 08022 (“Almirall”), and Almirall LLC (formerly named, Aqua Pharmaceuticals, LLC), a limited liability company organized and existing under the laws of the Commonwealth of Pennsylvania, with a principal place of business at 707 Eagleview Blvd., Suite 200, Exton, PA 19341 (“Almirall LLC”).
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • April 23rd, 2002 • Avi Biopharma Inc • Pharmaceutical preparations • Minnesota
THIS LICENSE AND DEVELOPMENT AGREEMENT (this "Agreement") is made and entered into as of June 20, 2001 between AVI BIOPHARMA, INC. ("AVI"), an Oregon corporation, and MEDTRONIC, INC. ("Medtronic"), a Minnesota corporation.
RECITALSLicense and Development Agreement • March 16th, 2007 • Inhibitex, Inc. • Biological products, (no disgnostic substances) • Delaware
ContractLicense and Development Agreement • January 31st, 2024 • Kiora Pharmaceuticals Inc • Pharmaceutical preparations
AMENDMENT NO. 1 TO LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • August 12th, 2005 • Novadel Pharma Inc • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 1 TO LICENSE AND DEVELOPMENT AGREEMENT (this “Amendment”), dated as of August 8, 2005, is entered into by and between NOVADEL PHARMA, INC., a Delaware corporation (“NovaDel”), and HANA BIOSCIENCES, INC., a Delaware corporation (the “Licensee”). NovaDel and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • April 11th, 2006 • Avi Biopharma Inc • Pharmaceutical preparations • Indiana
THIS LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”) is made and entered into as of March 10, 2006 between AVI BIOPHARMA, INC. (“AVI”), an Oregon corporation, and COOK GROUP INCORPORATED (“Company”), an Indiana corporation.
Confidential Treatment Requested by BioDelivery Sciences International, Inc. IRS Employer Identification No. 35-208985 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with...License and Development Agreement • January 11th, 2012 • Biodelivery Sciences International Inc • Pharmaceutical preparations • Pennsylvania
This LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”) is made and effective as of January 5, 2012 (the “Effective Date”) by and among Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius”), BioDelivery Sciences International, Inc., a Delaware corporation (“Parent”), and, to the extent deemed a party hereto pursuant to Section 15.19 hereof, Arius Two, Inc., a Delaware corporation (“Arius Two”), each having its principal office at 801 Corporate Center Drive, Suite 210, Raleigh, NC 27607 (Arius, Parent, and, to the extent deemed a party hereto pursuant to Section 15.19 hereof, Arius Two together are referred to as “BDSI”) and Endo Pharmaceuticals Inc., a Delaware corporation, having its principal office at 100 Endo Boulevard, Chadds Ford, PA 19317, USA (“Endo”) (each of Arius, Parent, and, to the extent deemed a party hereto pursuant to Section 15.19 hereof, Arius Two and Endo being a “Party,” and collectively, the “Parties”).
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission. LICENSE AND DEVELOPMENT...License and Development Agreement • August 10th, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • California
THIS LICENSE AND DEVELOPMENT AGREEMENT is entered into as of the 26th day of February, 2003 (the “Effective Date”) by and between XTL BIOPHARMACEUTICALS LTD. (“XTL”), and B&C BIOPHARM CO., LTD. (“B&C”)
AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • November 7th, 2018 • Melinta Therapeutics, Inc. /New/ • Pharmaceutical preparations
This Amendment No. 2 (“Amendment No. 2”) to the EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT, dated as of May 8, 2013 and amended as of September 26, 2013, by and between CEMPRA PHARMACEUTICALS, INC. (“Cempra”) and TOYAMA CHEMICAL CO., LTD. (“Toyama”) is hereby effective as of September 12, 2018. Capitalized terms not defined herein shall have the meaning given to them in the Agreement.
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • February 6th, 2008 • Cypress Semiconductor Corp /De/ • Semiconductors & related devices • California
This License and Development Agreement (“Agreement”) is made and entered into effective as of March 24, 2006 (the “Effective Date”) by and between Simtek Corporation, a Colorado corporation, located at 4250 Buckingham Drive, Suite 100 Colorado Springs, CO 80907 (“Simtek”) and Cypress Semiconductor Corporation, a Delaware corporation, located at 3901 North 1st Street, San Jose, CA 95134 (“Cypress”), either of which may hereafter also be referred to as a “Party,” or collectively as the “Parties” hereto.
RECITALSLicense and Development Agreement • March 31st, 1999 • Lynx Therapeutics Inc • Medicinal chemicals & botanical products
AMENDMENT NO. 2 TO LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • April 2nd, 2007 • Hana Biosciences Inc • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 2 TO LICENSE AND DEVELOPMENT AGREEMENT (this “Amendment”), dated as of May 15, 2006, is entered into by and between NovaDel Pharma, Inc., a Delaware corporation (“NovaDel”), and Hana Biosciences, Inc., a Delaware corporation (the “Licensee”). NovaDel and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
FIRST AMENDMENT TO AMENDED AND RESTATED SUPPLY, LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • August 10th, 2007 • Digital Angel Corp • Communications equipment, nec
This First Amendment to the Amended and Restated Supply, License, and Development Agreement dated December 27, 2005, is dated May 9, 2007 (the “Amended Agreement”) by and between Digital Angel Corporation (“Digital Angel”) and VeriChip Corporation (“VeriChip”), both Delaware corporations.
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 1 TO NON-EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • March 16th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment to Non-Exclusive License And Development Agreement (“Amendment No. 1”), effective as of April 12, 2021 (“Amendment No. 1 Effective Date”), is entered into by and between FUJIFILM CELLULAR DYNAMICS, INC., having a place of business at 525 Science Drive, Madison, WI 53711 (“FCDI”), and SANA BIOTECHNOLOGY, INC., having a place of business at 188 East Blaine Street, Suite 400, Seattle, WA 98102 (“Licensee”).
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • March 17th, 2014 • Galena Biopharma, Inc. • Pharmaceutical preparations • Delaware
This License and Development Agreement (as it may be amended as provided herein, this “Agreement”) is entered into as of January 13, 2014 (the “Effective Date”) by and among Galena Biopharma, Inc., a corporation organized under the laws of the State of Delaware, U.S.A. (“Galena”), and Apthera, Inc., a Delaware corporation and wholly owned subsidiary of Galena (“Apthera” and, together with Galena, “Licensor”), each having its principal place of business at 4640 S.W. Macadam Avenue, Suite 270, Portland, Oregon, U.S.A. 97239, on the one hand, and Dr. Reddy’s Laboratories Limited, a company organized under the laws of India, having its principal place of business at Door No. 8-2-337, Road No. 3, Banjara Hills, Hyderbad 50034, Andra Pradesh, India (“Licensee”), on the other hand. Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense and Development Agreement • January 23rd, 2009 • Inovio Biomedical Corp • Surgical & medical instruments & apparatus • Delaware
